Advertisement

Moderna's Bigger Catalyst: Full FDA Approval or Booster Authorization?

Moderna (NASDAQ: MRNA) awaits two decisions from the U.S. Food and Drug Administration. The company hopes to win full approval for its COVID-19 vaccine. It also wants the FDA to give a green light for a booster dose of its vaccine.